Antiretroviral therapy in children - Increased benefit from increased complexity

South African Medical Journal

Volumn 90, Issue 10 I, 2000, Pages 985-988

  Cotton, M F ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; PLACEBO; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CHILD; CHILD CARE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FOLLOW UP; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PNEUMOCYSTIS PNEUMONIA; PROGNOSIS; REVIEW; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT PLANNING; VERTICAL TRANSMISSION; VIRUS DETECTION; VIRUS TRANSMISSION;

AGE FACTORS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DRUG COSTS; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; SOUTH AFRICA; TREATMENT OUTCOME;

EID: 0033756937     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Pneumocystis carinii pneumonia in Los Angeles
2. Unexplained immunodeficiency and opportunistic infections in infants - New York, New Jersey, California
3. Isolation of a T-lymphotropic virus from a patient at risk for acquired immunodeficiency syndrome (AIDS)
4. Pathogenesis of human immunodeficiency virus infection
5. Guidelines for the use of antiretroviral agents in pediatric HIV infection
6. Place of antiretroviral drugs in the treatment of HIV-infected people in Africa
7. Survival in children with perinatally acquired human immunodeficiency virus type 1 infection
8. Mortality in a cohort of children born to HIV-1 infected women from Durban, South Africa
9. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection
11. A randomized study of combined zidovudinelamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection
12. The effect of continuous infusion of zidovudine (AZT) in children with symptomatic HIV infection
13. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease
14. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double blind placebo controlled trial
15. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection
16. Zidovudine, didanosine or both as initial treatment for symptomatic HIV-infected children
17. Combination therapy with stavudine (D4T) plus didanosine (ddI) in children with human immunodeficiency virus infection
18. Monotherapy in an era of combination therapy: Is there a benefit? Experience in HIV-1-infected symptomatic South African children
19. Anti-retroviral therapy for HIV-infected children - Towards maximal effectiveness
20. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children
21. Clinical and virological response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: A multicenter study in the Netherlands
22. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse transcriptase inhibitors in children infected with human immunodeficiency virus type 1
23. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1
24. Immunologic and virological responses to HAART in severely compromised HIV-1-infected children
25. Reduced replication of 3TC resistant HIV-1 variants in primary cells due to a defect of the reverse transcriptase enzyme
26. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
27. Prognosis in HIV-1 infection predicted by quantity of virus in plasma
28. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission
29. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-1-specific immune responses
30. The effect of changing antiretroviral therapy on human immunodeficiency viral load: Experience with fifty-four perinatally infected children
31. Genotyping leads to improved antiretroviral treatment choices in a group of heavily pretreated pediatric patients
32. Hydroxyurea and dinanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters
33. A phase 1 study of hydroxyurea in HIV-infected children receiving didanosine and/or stavudine
34. National and provincial estimated costs and cost effectiveness of a programme to reduce mother-to-child HIV transmission in South Africa
35. Medical care costs of children born to HIV-infected mothers, in Abidjan, Cote Ivoire 1996 - 1997